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Background: The 16/6-idiotype (16/6-Id) of the human anti-DNA antibody was found to induce experimental lupus
in naïve mice, manifested by production of autoantibodies, leukopenia and elevated inflammatory markers, as well
as kidney and brain involvement. We assessed behavior and brain pathology of naive mice injected intra-
cerebra-ventricularly (ICV) with the 16/6-Id antibody.
Methods: C3H female mice were injected ICV to the right hemisphere with the human 16/6-Id antibody or
commercial human IgG antibodies (control). The mice were tested for depression by the forced swimming test
(FST), locomotor and explorative activity by the staircase test, and cognitive functions were examined by the novel
object recognition and Y-maze tests. Brain slices were stained for inflammatory processes.
Results: 16/6-Id injected mice were cognitively impaired as shown by significant differences in the preference for a
new object in the novel object recognition test compared to controls (P = 0.012). Similarly, the preference for spatial
novelty in the Y-maze test was significantly higher in the control group compared to the 16/6-Id-injected mice (42% vs.
9%, respectively, P = 0.065). Depression–like behavior and locomotor activity were not significantly different between
the16/6-Id-injected and the control mice. Immunohistochemistry analysis revealed an increase in astrocytes and
microglial activation in the hippocampus and amygdala, in the 16/6-Id injected group compared to the control.
Conclusions: Passive transfer of 16/6-Id antibodies directly into mice brain resulted in cognitive impairments and
histological evidence for brain inflammation. These findings shed additional light on the diverse mosaic
pathophysiology of neuropsychiatric lupus.
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Neuropsychiatric systemic lupus erythematosus (NPSLE)
refers to a complex set of syndromes involving the central
nervous system (CNS) in up to 56% of lupus patients [1-5].
Due to the varied diagnostic criteria applied to define
NPSLE, the American College of Rheumatology has* Correspondence: kivitys@gmail.com
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reproduction in any medium, provided the orproposed a standard nomenclature of case definitions,
reporting standards and diagnostic testing recommen-
dations for the 19 neuropsychiatric Systemic lupus
erythematosus (SLE) syndromes [6]. While some of the
focal manifestations (for example, stroke) can be explained
by vasculitic or thrombotic lesions, the pathogenicity of
more diffuse manifestations of NPSLE (for example, cogni-
tive impairment, depression and psychosis) remains rela-
tively obscure. Nevertheless, studies have demonstrated the
importance of various factors involved in the development
of diffuse neuropsychiatric manifestations, such as the
presence of autoantibodies, inflammatory mediators (fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kivity et al. BMC Medicine 2013, 11:90 Page 2 of 9
http://www.biomedcentral.com/1741-7015/11/90example, cytokines, matrix metalloproteinases), neuropep-
tides and endocrine factors [7-10]. Other factors, such as
medications and primary neurologic and psychiatric disor-
ders, may play a major role as well.
More than 20 brain specific and non-specific autoanti-
bodies have been proposed to be involved in the
mechanism of NPLSE [11], including anti-neuronal [12],
anti-ribosomal–P [13,14], anti-phospholipid [15] anti-
bodies, as well as anti NR2/anti-DNA antibodies that
cross react with N-methyl-D-aspartate (NMDA) recep-
tors [3,16]. During the last two decades, anti-DNA
idiotypes were characterized, and found to play an im-
portant role in systemic lupus erythematosus and NPSLE
[17]. The 16/6 idiotype (Id) antibody is a human anti-
single-stranded-DNA (anti-ssDNA) monoclonal antibody
(mAb) originated from a patient with cold agglutinin dis-
ease [18]. The 16/6-Id was found to be polyspecific [19],
cross reacting with cytoskeletal proteins (vimentin),
platelets, lymphocyte membranes, pathogens such as
Klebsiela polysaccharides and Mycobacterium tuberculosis
glycoproteins, brain glycolipids and tumor cells [20-22].
The presence of 16/6-Id was detected in 30% of lupus
patients, and their levels were found to correlate with
disease activity [23,24]. Elevated titers of 16/6-Id were
also detected in NPSLE patients [25]. Deposits of 16/6-Id
were found in the skin, kidney and brain tissue [21,26,27],
and were found to bind human cortical brain tissue
sections ex vivo. The presence of circulating 16/6-Id
was detected in patients with other autoimmuine diseases
as well (for example, polymyositis, systemic sclerosis)
[28,29]. Immunization of naïve mice with the human anti-
DNA 16/6-Id mAb was shown to induce experimental
lupus manifested both serologically and clinically. A wide
profile of mice autoantibodies (for example, mouse 16/6-
Id, and antibodies against dsDNA, ssDNA, Ro, La, RNP,
Sm, histones, cardiolipin and phosphatydilserine), were
detected, as well as leukopenia, elevated erythrocyte sedi-
mentation rate (ESR), proteinuria and the deposition of
immunoglobulins in the kidney mesangium [30-32]. In
addition, recent-preliminary data showed histological brain
changes in mice with experimental SLE induced by active
immunization with the 16/6-Id (A. Marom and E. Mozes,
unpublished results). Therefore, we hypothesized that the
16/6-Ids have a pathogenic role in neuropsychiatric lupus.
In the present study we investigated the effect of 16/6-Id
on behavioral and cognitive functions, as well as on the
brain pathology of naïve mice injected intra-cerebra
-ventricularily (ICV) with the 16/6-Id.
Methods
Mice, antibody injection and experimental design
Mice
Three-month-old, female C3H mice were obtained from
Harlan Laboratories, Jerusalem, Israel, and were housedin the animal facility at Sheba Medical Center. The mice
were raised under standard conditions, 23 ± 1°C, 12-
hour light cycle (6:30 am to 6:30 pm) with ad libitum
access to food and water. The Sheba Medical Center
Animal Welfare Committee approved all procedures.
Monoclonal 16/6-Id expressing antibodies
The human monoclonal anti–DNA antibodies were
produced by a hybridoma derived from fusion of the
GM4672 lymphoblastoid cell line and peripheral blood
or splenic lymphocytes obtained from three lupus pa-
tients. The human mAb that bears the 16/6-Id (IgG1/k)
has been characterized previously [33]. The mAb was se-
creted by hybridoma cells that were grown in culture
and were purified by using a protein G-sepharose col-
umn (Pharmacia, Fine Chemicals, Uppsala, Sweden).
The injection process is based on a detailed protocol
reported by Shoenfeld et al. [34]. Mice were anesthe-
tized by intra-peritoneal (i.p.) injection of ketamine
(100 mg/kg) and xylazine (20 mg/kg). The skull was
carefully exposed, and a small hole was drilled with a
25-gauge needle above the right lateral ventricle (2
mm lateral to the midline and 2.5 mm posterior to the
bregma). A 27-gauge needle attached to a Hamilton syr-
inge was inserted at this point to a depth of 2 mm, where
preliminary tests had confirmed accurate ICV placement
by injection of dye. Then 1 μl of anti-DNA 16/6-Id mAb
or control IgG was slowly infused, the needle was with-
drawn and the skin over the scalp was sutured. All anti-
body solutions used contained 6 mg protein/ml. Each
mouse received only a single injection.
Experimental design
Twenty-one CH3 mice were injected ICV to the right
hemisphere, 11 with human 16/6-Id antibodies and 10
with commercial human IgG antibodies (control). The
forced swimming test (FST) was performed at Days 16
and 23 after antibody injection, the staircase test at Days
14 and 26, the novel object recognition at Days 19 and
20 and the Y-maze test at Day 21. At Day 24, under
anesthesia, a systemic perfusion was performed, and the
brains were collected. Immunofluorescence staining was
performed to detect markers of inflammation or neur-
onal degeneration (see below).
Cognitive and behavioral tests
Forced swimming test
This test is based on Porsolt et al.‘s description [35].
Mice were placed in individual glass beakers (height 39
cm, diameter 21.7 cm) with water 15 cm deep at 25°C.
On the first day, mice were placed in the cylinder for a
pretest session of 15 minutes, and later were removed
from the cylinder, and then returned to their home
cages. Twenty-four hours later (Day 2), the mice were
Kivity et al. BMC Medicine 2013, 11:90 Page 3 of 9
http://www.biomedcentral.com/1741-7015/11/90re-exposed to the swimming condition in a similar envir-
onment, and then subjected to a test session for six mi-
nutes. The behavioral measure scored was the duration
(in seconds) of immobility, defined as the absence of
escape-oriented behaviors, such as swimming, jumping,
rearing, sniffing or diving, recorded during the six-
minute test. A depression-like behavior was considered
as an increased immobility time.
Staircase test
Locomotor and explorative activity was evaluated by the
staircase test, as described previously by Katzav et al.
[15]. This test analyzes locomotor and exploratory activ-
ities (stair-climbing) and anxiety (rearing). The staircase
maze consisted of a polyvinyl chloride enclosure with
five identical steps, 2.5 × 10 × 7.5 cm. The inner height
of the walls was constant (12.5 cm) along the whole
length of the staircase. The box was placed in a room
with constant lighting and isolated from external noise.
Each mouse was tested individually. The animal was
placed on the floor of the staircase with its back to the
staircase. The number of stairs climbed and the number
of rears were recorded during a three-minute period.
Climbing was defined as each stair on which the mouse
placed all four paws; rearing was defined as each in-
stance the mouse rose on hind legs (to sniff the air), ei-
ther on the stair or against the wall. The number of
stairs descended was not taken into account. Before each
test, the animal was removed and the box cleaned with a
diluted alcohol solution to eliminate smells.
Novel object recognition test
This is a visual recognition memory test based on a
method described by Tordera et al. [36]. The apparatus,
an open field box (50 × 50 × 20 cm), was constructed
from plywood painted white. Three phases (habituation,
training and retention) were conducted on two separate
test days. Before training, mice were individually habitu-
ated by allowing them to explore the box for one hour.
No data were collected at this phase. During training
sessions, two identical objects were placed into the box
in the northwest and southeast corners (approximately
5 cm from the walls), 20 cm away from each other (sym-
metrically) and then the individual animal was allowed
to explore for five minutes. Exploration of an object was
defined as directing the nose to the object at a distance
of ≤1 cm and/or touching it with the nose; turning
around or sitting near the object was not considered as
exploratory behavior. The time spent in exploring each
object was recorded. The animals were returned to their
home cages immediately after training. During the reten-
tion test, the animals were placed back into the same
box after a four-hour interval, and allowed to explore
freely for five minutes. One of the familiar objects usedduring training was replaced by a novel object. All ob-
jects were balanced in terms of physical complexity and
were emotionally neutral. The box and the objects were
thoroughly cleaned by 70% alcohol before each session
to avoid possible instinctive odorant cues. A preference
index, a ratio of the amount of time spent exploring any
one of the two items (old and new in the retention ses-
sion) over the total time spent exploring both objects,
was used to measure recognition memory. Individual ani-
mals demonstrating insufficient task performance were
excluded from later specific statistical analyses for the fol-
lowing reasons: (1) non-exploration, which was defined as
no objection interaction or (2) technical malfunctions dur-
ing data collection.
Y maze test
The Y maze test was used to assess spatial memory. It
was comprised of three arms, built of black Perspex.
Each arm was 8 × 30 × 15 cm at an angle of 120° from
the others. One arm was randomly selected as the start
arm. Each mouse was placed twice in the start arm. On
the first trial, lasting for five minutes, one of the other
two arms was randomly chosen to be blocked whereas
on the second trial, lasting for two minutes, both arms
were open. The two trials were separated by a two-
minute interval, during which the mouse was returned
to its home cage. The time spent in each of the arms
was measured. Between each trial and between each
mouse, the maze was cleaned with a 70% alcohol solu-
tion and dried. Discrimination of spatial novelty was
assessed by a preference index [37]: time in the new
arm - time old arm/time in the new arm + time in the
old arm, assessing spatial memory. The mouse is
expected to recognize the old arm as old and spend
more time in the new arm.
Immunofluorescence staining
Brain perfusion and fixation
The mice were anesthetized by an i.p. injection of keta-
mine (100 mg/kg) and xylazine (20 mg/kg) and sacrificed
by transcardiac perfusion with phosphate buffered saline
(PBS) followed by perfusion with 4% paraformaldehyde
(PFA, Sigma-Aldrich Israel Ltd., Rehovot Israel) in phos-
phate buffer (PO4, pH 7.4). After perfusion, the brain was
quickly removed and fixed overnight in 4% PFA (in PO4,
pH 7.4) at 4°C. On the following day, the brain was
cryoprotected by immersion in 30% sucrose in 0.1M PO4
(pH 7.4) for 24 to 48 hours at 4°C before brain cutting.
Brain cutting and preservation
Frozen coronal sections (30 to 50 μm) were cut on a
sliding microtome (Leica Microsystems GmbH, Wetzlar,
Germany), collected serially and kept in a cryoprotectant
at −20°C until staining. Staining was performed as
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were used for immunohistochemistry. Brain sections
were stained free-floating, incubated with the first anti-
bodies overnight at 4°C. The slices were then washed in
PBS + 0.1% Triton X-100, and incubated at room
temperature for one hour with the corresponding fluor-
escent chromogens-conjugated secondary antibody. Sec-
tions were stained for specific antigens with antibodies
against activated microglia (anti-Iba1, pAb, Abcam,
Cambridge, UK) and astrocytes (anti-GFAP mAb, Dako,
Carpinteria, CA, USA). Counter staining was performed
with Hoechst (Sigma-Aldrich Israel Ltd., Rehovot Israel).
Statistical analysis
Results are expressed as the mean ± SEM. The differ-
ences in mean for average immobility time in the FST,
the staircase test parameters (number of rearing and
stair-climbing events), novel object recognition and Y-
maze tests were evaluated by T-test. Significant results
were determined as P <0.05.
Results
Cognitive and behavioral performance
The results of cognitive performance in the novel object
recognition test are presented as the proportion time
spent near objects (new and old) in both groups (Figure 1).
There was a significant preference for attention to the
new object in the control group (64% time spent near the
new object compared to 36% time spent near the old ob-
ject, P = 0.012), while no difference in the preference was
seen in the mice injected with 16/6-Id (56% vs. 44% timeFigure 1 16/6-Id injected mice displayed impaired performance
in the novel object recognition test. Results are presented as the
proportion of time spent near the old and new objects by the 16/6-
Id (gray bars) and IgG control (black bars) injected mice. The control
mice (IgG) significantly preferred the new object (64% vs. 36% for
the proportion time near the new vs. old objects respectively; P =
0.01), while the 16/6-Id injected mice had no significant preference
to either objects (56% vs. 44% new vs. old; P = 0.5). Results
presented as mean ± SEM. * Statistically significant (P <0.05).spent near the new object vs. old object, P = 0.655). This
suggests a specific visual recognition memory impairment
in the 16/6-Id mice. Similarly, cognitive performance in
the Y-maze test is presented as a preference index for new
(additional percent time spent in the novel arm) in both
groups (Figure 2). The control IgG mice spent 46% add-
itional time in the new lane while the mice injected with
16/6-Id spent 9% additional time in the new lane (P =
0.015 by t-test).
In the forced swimming test there was no significant
difference between 16/6-Id injected and control mice in
depression-like behavior at Days 16 and 24 after injec-
tion. Average immobility times of the control mice vs.
16/6-Id injected mice were 117.6 ± 65.9 vs. 160 ± 72.8
(P = 0.159 by t-test) and 182.5 ± 45.4 vs. 205.7 ± 42.7
sec (P = 0.238 by t-test) on Days 16 and 24, respectively.
In the staircase test, there was no significant difference
between the average rearing and stair-climbing counts,
among mice from control-IgG vs. 16/6-Id (23.7 ± 2.6 vs.
21.8 ± 2.5 rearings, and 24.5 ± 2.3 vs. 16.5 ± 4.4 stair-
climbing events, respectively, P >0.016). The results also
did not change from Day 14 to 26.
Brain pathology
Brain sections were stained for activated microglia and
astrocytes (as markers for inflammation). The 16/6-Id
injected mice demonstrated increased microglial activa-
tion (Iba-1 staining), at the hippocampus (CA1, CA3,
dentate gyrus, stratum radiatum) as well as the amyg-
dala, compared to IgG control (Figure 3). The differenceFigure 2 16/6-Id injected mice displayed impaired spatial
memory in the Y-maze test. Results are presented as the
proportion of time (mean ± SEM) spent in the new arm introduced
by the 16/6-Id (gray bars) and IgG control (black bars) injected mice.
In the figure it is shown that the control group (IgG injected) spent
more time in the new lane as compared to the 16/6 injected group.
They have recognized the old lane as known and preferred
exploring the new lane, which means that their spatial memory is
conserved. There was a significant difference in additional time
spent in the new lane between the 16/6 and IgG group (0.46 vs.
0.09, P = 0.02 respectively). * Statistically significant (P <0.05).
Figure 3 Increased brain inflammation (activated microglia) in 16/6-Id mice in the hippocampal regions (CA1, CA3). Staining of activated
microglia (green, white arrows) was more prominent in the 16/6-Id injected mice brains (A, C) compared to control mice brains (B, D) in the
hippocampal regions CA1 (A, B) and CA3 (C, D). Hoechst nucleus staining – blue, GFAP staining – red. Magnification ×40.
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neucortex and piriform cortex, between 16/6-Id and
control-IgG mice. Increased staining for astrocytes
(GFAP staining) was also noted in the CA3 hippocampal
region in the 16/6-Id injected mice compared to controls
(Figure 4).
Discussion
In the present study we have observed that passive
transfer of 16/6-Id antibodies directly to mice brains
resulted in a selective cognitive impairment, expressed
as visual recognition and spatial memory deficits. De-
pressive behavior (FST) and locomotor activity (staircase
test) were not altered in the 16/6-Id injected mice, when
compared to the control group. Our findings suggest
that 16/6-Id antibodies may have a role in the pathogen-
esis of cognitive impairment observed in some patients
with SLE [8].
Immunostaining of brain sections from both groups
revealed increased presence of activated microglia and
astrocytes, in the hippocampal region of the 16/6-Id
injected mice, compared to the controls. The hippocam-
pus has an important function in memory processing,
therefore, its damage by an inflammatory processes may
affect cognitive performance in the 16/6-Id injected
mice. Astrocytes in steady state conditions are mainly
responsible for biochemical support and several otherchemical roles such as maintenance of extracellular ion
balance. However, in special situations, astrocytes may
increase in number as an inflammatory reaction aimed
for scaring and repairing CNS tissue. Microglia serve as
scavengers and are activated in an inflammatory reac-
tion. The presence of more astrocytes (gliosis) or the ac-
tivation of microglia in brain tissue can implicate an
inflammatory state. Our hypothesis regarding the patho-
genesis of 16/6-Id antibodies induced-brain impairment
includes several mechanisms: 1) Neuronal degeneration
may be caused by direct or indirect injury to hippocam-
pal area. For example, recently Berry et al. demonstrated
that anti-ATP synthase autoantibodies, purified from
Alzheimer’s disease patients, can lead to cognitive im-
pairment and hippocampal neuron apoptosis in naïve
mice [38]. Other neurotoxic autoantibodies, such as anti-
phospholipid and anti-ribosomal P antibodies, were shown
to penetrate living cells and cause functional cellular injury
and apoptosis by inhibiting protein synthesis [39,40]. 2)
Neuronal function modification. 16/6-Id antibodies may
recognize and bind antigens expressed on neurons of the
hippocampus and may affect brain cells by alter signaling,
cell function and neurotransmitter pathways [41]. 3) Brain
inflammation. Injection of 16/6-Id antibodies may lead to
brain inflammation involving activation of microglia and
astrocytes, and the production of pro-inflammatory
cytokines. This inflammatory response can disrupt the
Figure 4 Increased brain inflammation (astrocyes) in 16/6-Id mice in the hippocampal region (CA3). Staining of astrocytes (red) in the
hippocampal CA3 region was more prominent in the 16/6-Id injected mice brains (A) compared to control mice injected with commercial IgG
(B). Hoechst nucleus staining - blue. Magnification ×40.
Kivity et al. BMC Medicine 2013, 11:90 Page 6 of 9
http://www.biomedcentral.com/1741-7015/11/90blood–brain barrier, facilitating entry into the brain by in-
flammatory factors, including circulating cells of the im-
mune system, cytokines, immune-complex mediated small
vessel inflammation, and complement components. The
inflammatory reaction may induce cognitive changes ob-
served in the injected mice.
We have extensively studied the pathogenesis of differ-
ent autoantibodies and their influence on the brain. In-
jection of anti-ribosomal-P antibodies ICV to naïve mice
resulted in depressive-like behavior in these mice
[42,43]. In another study, we found that injection of
antiphospholipid syndrome patients with antibodies in-
duced memory deficits and hyperactivity [15,44]. This
suggests that a certain antibody is linked with each spe-
cific disease manifestation. The presence of numerous
autoantibodies, at least 174 in SLE and 20 in NPSLE,
which might have a role in the mechanism of the disease
were reported during the past years [11,45]. This may
explain the diversity of 19 neuropsychiatric manifesta-
tions which can be demonstrated in more than 50% of
SLE patients [46]. We propose a hypothesis, that in
NPSLE patients different manifestations are the result of
an interplay among various auto-antibodies and genetic
and environmental factors. For this process to occur,
auto-antibodies produced in the body must be able to
cross the blood–brain barrier (BBB). It is presumed that
the BBB can become transiently “unlocked” following an
inflammatory insult, an immune complex damage or ex-
posure to infectious endotoxins (for example, lipopoly-
saccharide, LPS), allowing antibody penetration. In
addition, different auto-antibodies may attach to differ-
ent epitopes, expressed unevenly in different brain areas
or neuronal networks. In the studies of Diamond et al.,
anti-DNA antibodies which can cross-react with the
NR2 - anti-NMDA receptor were found in the sera, CSF
and brains of SLE patients [16,47]. These antibodies
were shown to alter brain cell function and to mediate
apoptotic death in vivo and in vitro [16,47]. In theirexperiments, the BBB was breached temporarily by in-
jection with LPS to imitate an infection [48], while
others used noradrenalin to imitate a stressful condition;
both conditions were implicated in triggering disease
flare-ups in SLE and NPSLE patients. The studies of
Diamond et al. added another layer to the current un-
derstandings regarding the role of different auto-antibodies
in the pathogenesis of NPSLE. Another technique to by-
pass the BBB was used by us in several experiments. In the
ICV technique, antibodies were injected directly into the
lateral ventricle in the mouse brain, allowing antibody dis-
persal throughout the brain tissue. In our previous studies,
an experimental NPSLE was induced by passive transfer of
anti-ribosomal-P antibodies directly to mice brains [43].
The intra-cerebra-ventricularly injected mice exhibited a
depression-like behavior, not associated with motor or cog-
nitive deficits, and was significantly attenuated by prolong
treatment with an anti-depressant (fluoxetine), but not
with anti-psychotic drug (haloperidol). Interestingly, the
anti-ribosomal-P antibody specifically stained neurons which
are related to limbic and olfactory brain areas: the hippo-
campus, cingulate cortex and the primary olfactory piriform
cortex [43]. The depressed mice also exhibited a decreased
smell threshold capability [42], as well as olfactory and lim-
bic imaging alterations, when manganese-enhanced-mag-
netic resonance imaging (MRI) was performed [49].
Another issue of this puzzle was stressed almost two de-
cades ago when the importance of the idiotypic network
in the induction of various autoimmune diseases was ac-
knowledged [22,50]. One proposed mechanism of action
of the 16 /6-Id is via the idiotypic network, in which injec-
tion of human anti-DNA 16/6-Id mAbs induces the
generation of anti-Id, and anti-anti-Id, and so on. The pro-
duction of 16/6-Id was found to be induced also by several
infectious agents (for example, Klebsiella pneumonia
[51,52] and Mycobacterium tuberculosis [53]); this could
point to the role of infections in initiating the disease in a
genetically susceptible individual [54].
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other autoimmune diseases, such as PM/DM and sclero-
derma without them expressing central nervous symp-
toms is interesting. Perhaps, in some diseases (for
example, SLE) a variety of systemic factors enable the al-
tering of BBB permeability. These factors may include
other circulating antibodies, inflammatory elements, as
well as vasogenic agents, growth factors and free radicals.
This phenomenon is not unusual in the autoimmunity
field, for instance, anti-Ro antibodies are associated with
myositis or sub-acute skin manifestations in some SLE pa-
tients and not in Sjogren patients.
The current finding, that the 16/6-Id is related to
spatial novelty and visual recognition memory impair-
ments in mice, may attest for immune-mediated damage
to brain areas relevant for these functions. There is a
wide agreement that spatial long-term memory and ob-
ject recognition is dependent on the functioning of the
hippocampal region [55]. Taken together, these concepts
may promote the idea for a treatment for NPSLE via
blocking or inhibiting the 16/6-Id. This can be done per-
haps by treatment with intravenous gamma-globulin,
which harbors anti-idiotypic antibodies itself, and has
shown some efficacy in the treatment of NPSLE patients
[56]. Other therapeutic means may involve the utilization
of inhibitory peptides based on the complementarity de-
termining region of anti-DNA antibodies. Indeed, such a
peptide was shown to be effective in animal models and in
a limited number of lupus patients [57-59].
Conclusions
Passive transfer of anti-DNA 16/6-idiotype directly to
mice brains resulted in cognitive impairment, supported
by cognitive testing impairments, and changes in brain
histological analysis. Therefore, the 16/6-idiotype may
have a role in cognitive decline, as well as other neuro-
psychiatric manifestations, which are found in lupus
patients.
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